Skip to content

Comparison of the effectiveness of sub-patellar fat pad and intra-articular glucocorticoids injection in knee osteoarthritis patients with Hoffa’s synovitis: a prospective multicenter randomized controlled multiple-blind trial

Comparison of the effectiveness of sub-patellar fat pad and intra-articular glucocorticoids injection in knee osteoarthritis patients with Hoffa’s synovitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400080474
Enrollment
Unknown
Registered
2024-01-30
Start date
2024-05-29
Completion date
Unknown
Last updated
2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Interventions

Intervention Group:Injected with 40 mg (1 mL) of triamcinolone acetonide hydrochloride into the subpatellar fat pad under ultrasound guidance
Control Group:Injected with 40 mg (1 mL) of triamcinolone acetonide hydrochloride into the knee joint cavity under ultrasound guidance.

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Above 40 years old; 2. Patients with unilateral knee joint pain; 3. The WOMAC pain score (range 0-20 points) on this side in the past week was 8-18 points; 4. This side meets the ACR clinical classification criteria for knee osteoarthritis; 5. KL >= 2 on this side 6. MRI examination of this side shows Hoffa’s synovitis; 7. Patients who are scheduled to reveive intra-articular steroid injection treatment.

Exclusion criteria

Exclusion criteria: 1. Accompanied by rheumatoid arthritis, gouty arthritis and other diseases that affect lower limb symptom scores; 2. Have been scheduled to undergo joint surgery; 3. Patients who have had surgery in the knee joint in the past; 4. Taking oral glucocorticoid drugs; 5. Patients who have received intra-articular glucocorticoid injection in the past 6 months; 6. Allergy to glucocorticoids; 7. Have contraindications for MRI examination; 8. Patients with type I or type 2 diabetes with poor blood sugar control; 9. Patients with a history of peptic ulcer; 10. Unable to complete follow-up and questionnaire surveys independently; 11. Patients who are unwilling to join the trial.

Design outcomes

Primary

MeasureTime frame
Superiority indicator: Difference in Hoffa’s synovitis improvement rate between the two groups based on the MOAKS scoring system;Non-inferiority indicator:The difference in improvement in WOMAC pain scores (0-20 points) between the two groups ;

Secondary

MeasureTime frame
Difference in Hoffa’s synovitis improvement rate between the two groups based on the MOAKS scoring system;The difference in improvement in WOMAC pain scores (0-20 points) between the two groups ;NRS pain questionnaire scores;WOMAC questionnaire scores (function, joint stiffness and total scores);Improvement rate of effusion synovitis (according to MOAKS system);Articular cartilage thickness changes (MRI quantification);ICOAP questionnaire scores;EQ5D questionnaire scores;OARSI-OMERACT response rate;

Countries

China

Contacts

Public ContactWang Qiuke

Shanghai Sixth People's Hospital

qiukewang@gmail.com+86 189 3017 5992

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 16, 2026